|Alanine aminotransferase (ALT)
Alanine aminotransferase (AST)
Alkaline Phosphatase (ALP)
C-Reactive Protein (CRP)
|Hemoglobin A1C (HBA1c)
Ion-specific electrode (ISE: Na, K, CL) (serum)
Lactate dehydrogenase (LDH)
Lipemia, Icterus, Hemolysis (LIH)
Urine Total Protein (MTP)
Urea Nitrogen (BUN)
Make Decisions with Confidence Early in Preclinical CVMD Research with CrownBio’s Reliable Clinical Chemistry and Biomarker Services
CrownBio offers clinical chemistry and biomarker services to provide robust, high quality data for the early preclinical development of CVMD drugs and diagnostics. Our expertise covers a range of models and therapeutic areas, with a particular focus on cardio-metabolic endpoints in rodents and non-human primates. CrownBio provides a rapid, cost effective way to analyze samples as a standalone service, or as a supplement to in vivo studies.
Non-GLP Clinical Chemistry and Biomarker Services
Analytes listed in the following sections are subject to change. Please contact your local business development specialist for our current offerings. Additional assays are available with a validation lead time of approximately 2-3 weeks.
Clinical Chemistry Services
CrownBio can efficiently analyze the effects of agents through a comprehensive portfolio of clinical chemistry assays that provide valuable information about drug efficacy, candidate selection, and enzymatic activity. The following portfolio of assays were developed on the Beckman-Coulter AU480 Chemical System and are available through CrownBio as a service to help advance preclinical cardiovascular and metabolic disease development programs:
View Clinical Chemistry Assays
Translational biomarkers are used throughout drug development to help elucidate underlying pathophysiology, understand agents’ mechanisms of action, measure efficacy, and stratify patient populations. CrownBio recognizes the importance of biomarkers from target validation studies to candidate selection and our scientists can develop, validate, and run custom assay services in addition to the following set of immunoassay services routinely performed to help inform decision making in cardiovascular and metabolic disease development. Choose from the following platforms:
MesoScale Discovery Biomarker Assays
Run your samples on MSD’s electrochemiluminescent technology platform. Using the Sector S600, biomarkers can be customized into a V-PLEX or U-PLEX plate with up to 10 biomarkers of your choice.
View MesoScale Discovery Assays
|Human and Nonhuman Primate Assays (NHP Valided Kits)|
Colorimetric ELISA Biomarker Assays
Evaluate biomarkers on our standard, colorimetric, enzyme based ELISA platform.
View ELISA Assays
|Human and NHP Assays|
|Other Species Assays|
Turn Around Time: 5 to 7 business days (clinical chemistry), 7-10 business days (MSD & ELISA)
Data Delivery Format: Excel File, unless otherwise requested
CrownBio recognizes the importance of providing reliable data to our clients, so we have instated rigorous quality control and assay qualification procedures to ensure precision and accuracy. We provide high quality results that our clients can trust when making go/no-go decisions in their CVMD preclinical research programs. Please see below for examples of standard curves generated for two important cytokines.